XML 115 R110.htm IDEA: XBRL DOCUMENT v2.4.0.8
Other Consolidated Financial Statement Detail (Details) (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Cash Paid During the Year      
Interest $ 53,600,000 $ 65,400,000 $ 66,700,000
Income taxes 643,200,000 526,600,000 332,700,000
Other Income (Expense), Net      
Interest income 8,200,000 29,500,000 19,200,000
Interest expense (31,900,000) (36,500,000) (33,000,000)
Impairment of investments (2,800,000) (5,500,000) (9,900,000)
Gain (loss) on sales of investments, net 21,700,000 10,600,000 18,800,000
Foreign exchange gains (losses), net (15,200,000) (2,500,000) (6,300,000)
Other, net (14,900,000) 3,700,000 (2,300,000)
Total other income (expense), net (34,930,000) (744,000) (13,477,000)
Accrued Expenses and Other      
Employee compensation and benefits 343,400,000 248,500,000  
Revenue-related rebates 264,900,000 191,000,000  
Deferred revenue 172,700,000 148,000,000  
Royalties and licensing fees 160,700,000 45,200,000  
Clinical development expenses 55,200,000 51,600,000  
Current portion of contingent consideration obligations 29,000,000 22,400,000  
Construction in progress accrual 25,000,000 12,300,000  
Collaboration expenses 18,700,000 37,400,000  
Other 285,600,000 223,500,000  
Total accrued expenses and other $ 1,355,187,000 $ 979,945,000